Form 4: Glycomimetics COO Sells Shares
Insider Transaction (Form 4)
Jonathan Mcneill, President and COO of Glycomimetics Inc, sold 4,570 shares of common stock on September 16, 2026.
Summary
- Open-market sale: disposed of 731 Ordinary Shares at $17.90 ($13,085) on September 16, 2026; holds 138,427 after (Direct).
- Open-market sale: disposed of 3,839 Ordinary Shares at $16.71 ($64,150) on September 18, 2026; holds 134,588 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $77,235 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jonathan Mcneill — Officer (President and COO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Open-market sale | Ordinary Shares | 731 | $18 | $13.1K | 138,427 |
| 2026-09-18 | Open-market sale | Ordinary Shares | 3,839 | $17 | $64.1K | 134,588 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Open-market sale (731 shares) |
| 2026-09-18 | Open-market sale (3,839 shares) |
Keywords
insider transaction, Form 4, CBIO, CRESCENT BIOPHARMA, INC., bearish, Jonathan Mcneill
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.